GenMark Diagnostics, Inc., a molecular diagnostics company, develops and commercializes molecular tests based on its proprietary eSensor electrochemical detection technology. It provides ePlex instrument and respiratory pathogen panel, which integrates automated nucleic acid extraction and amplification with its eSensor detection technology to enable operators using ePlex system to place patient sample directly into its test cartridge and obtain results. The company offers XT-8 instrument, and related diagnostic and research tests, as well as certain custom manufactured reagents that enable reference laboratories and hospitals to support a range of molecular tests with a workstation and disposable test cartridges. It also provides diagnostic tests for use with its XT-8 system that includes respiratory viral panel, cystic fibrosis genotyping test, thrombophilia risk test, a warfarin sensitivity test, and hepatitis C virus genotyping test and associated custom manufactured reagents, as well as 2C19 genotyping test. The company sells its products through direct sales and technically specialized service organization in the United States and Europe. GenMark Diagnostics, Inc. is headquartered in Carlsbad, California.
Industry, Sector and Symbol
Industry Surgical & medical instruments
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:GNMK
CUSIPN/A
Phone760-448-4300
Debt
Debt-to-Equity Ratio0.24
Current Ratio2.79
Quick Ratio2.45
Price-To-Earnings
Trailing P/E Ratio-5.84
Forward P/E Ratio-9.18
P/E GrowthN/A
Sales & Book Value
Annual Sales$52.52 million
Price / Sales7.46
Cash FlowN/A
Price / CashN/A
Book Value$1.29 per share
Price / Book5.48
Profitability
EPS (Most Recent Fiscal Year)($1.21)
Net Income$-61,850,000.00
Net Margins-97.90%
Return on Equity-77.35%
Return on Assets-46.77%
Miscellaneous
Employees517
Outstanding Shares55,410,000
GenMark Diagnostics (NASDAQ:GNMK) Frequently Asked Questions
What is GenMark Diagnostics' stock symbol?
GenMark Diagnostics trades on the NASDAQ under the ticker symbol "GNMK."
How were GenMark Diagnostics' earnings last quarter?
GenMark Diagnostics, Inc (NASDAQ:GNMK) issued its earnings results on Tuesday, May, 1st. The medical equipment provider reported ($0.21) EPS for the quarter, beating the Thomson Reuters' consensus estimate of ($0.22) by $0.01. The medical equipment provider had revenue of $20.65 million for the quarter, compared to the consensus estimate of $17.12 million. GenMark Diagnostics had a negative net margin of 97.90% and a negative return on equity of 77.35%. View GenMark Diagnostics' Earnings History.
When is GenMark Diagnostics' next earnings date?
What price target have analysts set for GNMK?
6 brokers have issued 12-month target prices for GenMark Diagnostics' shares. Their predictions range from $8.00 to $13.00. On average, they expect GenMark Diagnostics' share price to reach $10.60 in the next year. View Analyst Ratings for GenMark Diagnostics.
What are Wall Street analysts saying about GenMark Diagnostics stock?
Here are some recent quotes from research analysts about GenMark Diagnostics stock:
- 1. Needham & Company LLC analysts commented, "On 4/19/18, bioMerieux announced its 1Q18 results, which included 47% FilmArray growth fueled partly by the severe flu season. bioMerieux’s BioFire FilmArray is the market-leading syndromic panel molecular testing system. We estimate that bioMerieux ended 1Q18 with a FilmArray installed base of ~6,750. We believe that bioMerieux’s strong FilmArray growth indicates that the syndromic panel testing market remains significantly under-penetrated and we have increased confidence that GNMK can exceed the 1Q18 revenue consensus when it reports on 5/1/18." (4/24/2018)
- 2. According to Zacks Investment Research, "GenMark Diagnostics, Inc. is a molecular diagnostics company focused on developing and commercializing its proprietary eSensor(R) detection technology. The eSensor® XT-8 system is the second generation in GenMark Dx's eSensor® platform, utilizing electrochemical detection technology to detect nucleic acids on a microarray. The XT-8 System enables multiplex detection of DNA and RNA targets. The Company has developed four diagnostic tests for use with its XT-8 System. Its Cystic Fibrosis Genotyping Test, which detects pre-conception risks of cystic fibrosis, and its Warfarin Sensitivity Test, which determines an individual's ability to metabolize the oral anticoagulant warfarin, have received FDA clearance. It has also developed a Respiratory Viral Panel Test, which detects the presence of major respiratory viruses, and a Thrombosis Risk Test, which detects an individual's increased risk of blood clots. GenMark Diagnostics, Inc. is based in Pasadena, California. " (1/25/2018)
- 3. BTIG Research analysts commented, "The fact that ACOR announced this morning that it will discontinue the tozadenant program (stopping dosing in all currently enrolled studies) came as little surprise following last week’s disclosure of safety issues (our thoughts here). Timing was the only marginal surprise, but based on additional analyses, the company determined that the recently instituted weekly white blood cell count screening may not be adequate to fully ensure the safety of patients. Though this morning’s headline has little incremental impact, it does highlight the added pressure on Inbrija (which is delayed itself following the RTF earlier this year) and formally removes the potential for near- term leverage in the business. Maintain Neutral." (11/20/2017)
Who are some of GenMark Diagnostics' key competitors?
Some companies that are related to GenMark Diagnostics include Glaukos (GKOS), Mazor Robotics (MZOR), Luminex (LMNX), Orthofix International (OFIX), Atrion (ATRI), Intersect ENT (XENT), Cardiovascular Systems (CSII), OraSure Technologies (OSUR), Cryolife (CRY), Tandem Diabetes Care (TNDM), Tactile Systems Technology (TCMD), AtriCure (ATRC), K2M Group (KTWO), Cerus (CERS) and AngioDynamics (ANGO).
Who are GenMark Diagnostics' key executives?
GenMark Diagnostics' management team includes the folowing people:
- Mr. Hany Massarany, CEO, Pres & Director (Age 57)
- Mr. Scott Mendel, Chief Financial Officer (Age 51)
- Ms. Jennifer Williams, Sr. VP of HR (Age 45)
- Mr. Michael Gleeson, Sr. VP of North American Commercial Operations (Age 43)
- Dr. John Faiz Kayyem, Founder (Age 54)
Has GenMark Diagnostics been receiving favorable news coverage?
News coverage about GNMK stock has been trending somewhat positive this week, according to Accern Sentiment. The research group identifies positive and negative news coverage by analyzing more than twenty million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. GenMark Diagnostics earned a media sentiment score of 0.01 on Accern's scale. They also gave headlines about the medical equipment provider an impact score of 47.52 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock's share price in the near term.
Who are GenMark Diagnostics' major shareholders?
GenMark Diagnostics' stock is owned by a variety of of retail and institutional investors. Top institutional investors include JPMorgan Chase & Co. (8.85%), BlackRock Inc. (5.61%), Bellevue Group AG (2.14%), Northern Trust Corp (1.16%), Thrivent Financial for Lutherans (1.08%) and Penn Capital Management Co. Inc. (0.76%). Company insiders that own GenMark Diagnostics stock include Brian Andrew Mitchell, Eric Stier, Hany Massarany, Jennifer Anne Williams, Jon Faiz Kayyem, Lisa M Giles, Michael Gleeson, Michael Kagnoff and Scott Mendel. View Institutional Ownership Trends for GenMark Diagnostics.
Which institutional investors are selling GenMark Diagnostics stock?
GNMK stock was sold by a variety of institutional investors in the last quarter, including Millennium Management LLC, Penn Capital Management Co. Inc., Northern Trust Corp, Wells Fargo & Company MN, Citadel Advisors LLC and BlackRock Inc.. Company insiders that have sold GenMark Diagnostics company stock in the last year include Brian Andrew Mitchell, Eric Stier, Hany Massarany, Jennifer Anne Williams, Jon Faiz Kayyem, Michael Gleeson and Scott Mendel. View Insider Buying and Selling for GenMark Diagnostics.
Which institutional investors are buying GenMark Diagnostics stock?
GNMK stock was acquired by a variety of institutional investors in the last quarter, including Bellevue Group AG, JPMorgan Chase & Co., A.R.T. Advisors LLC, MetLife Investment Advisors LLC and Thrivent Financial for Lutherans. Company insiders that have bought GenMark Diagnostics stock in the last two years include Lisa M Giles and Michael Kagnoff. View Insider Buying and Selling for GenMark Diagnostics.
How do I buy shares of GenMark Diagnostics?
Shares of GNMK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is GenMark Diagnostics' stock price today?
One share of GNMK stock can currently be purchased for approximately $7.07.
How big of a company is GenMark Diagnostics?
GenMark Diagnostics has a market capitalization of $398.42 million and generates $52.52 million in revenue each year. The medical equipment provider earns $-61,850,000.00 in net income (profit) each year or ($1.21) on an earnings per share basis. GenMark Diagnostics employs 517 workers across the globe.
How can I contact GenMark Diagnostics?
GenMark Diagnostics' mailing address is 5964 LA PLACE COURT, CARLSBAD CA, 92008. The medical equipment provider can be reached via phone at 760-448-4300 or via email at [email protected]
MarketBeat Community Rating for GenMark Diagnostics (GNMK)
MarketBeat's community ratings are surveys of what our community members think about GenMark Diagnostics and other stocks. Vote "Outperform" if you believe GNMK will outperform the S&P 500 over the long term. Vote "Underperform" if you believe GNMK will underperform the S&P 500 over the long term. You may vote once every thirty days.
